Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
about
Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraineCalcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cellsThe in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal arteryEndosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteriesCalcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.A Potential Preclinical Migraine Model: CGRP-Sensitized Mice.Possible sites of action of the new calcitonin gene-related peptide receptor antagonists.Headache-type adverse effects of NO donors: vasodilation and beyondOne hundred years of migraine research: major clinical and scientific observations from 1910 to 2010.Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex.DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons.Effect of carbon dioxide on calcitonin gene-related peptide secretion from trigeminal neurons.The Role of Salivary Neuropeptides in Pediatrics: Potential Biomarkers for Integrated Therapies.Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period.Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.The convergence hypothesis.Association between allergic rhinitis and migraine.Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraineCGRP and migraine: could PACAP play a role too?Genetic and biochemical changes of the serotonergic system in migraine pathobiologyActivity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.Fronto-turbinalis sinus expansion and headache.Chemical mediators of migraine: preclinical and clinical observations.Migraine and allergy: a review and clinical update.How to investigate and treat: migraine in patients with temporomandibular disorders.CGRP and NO in the trigeminal system: mechanisms and role in headache generation.CGRP receptor antagonists: design and screening.Biomarkers associated with migraine and their potential role in migraine management.Breath powered nasal delivery: a new route to rapid headache relief.The role of anti-CGRP antibodies in the pathophysiology of primary headaches.Neuropeptides as a Marker for Chronic Headache.An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.Headache attributed to airplane travel: diagnosis, pathophysiology, and treatment - a systematic review.The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion.Like cures like: a neuroimmunological model based on electromagnetic resonance.Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.Neuropeptides and ATP signaling in the trigeminal ganglion.Salivary glutamate is elevated in individuals with chronic migraine.Perivascular neurotransmitters: Regulation of cerebral blood flow and role in primary headaches.Novel Therapeutic Targets Against Spreading Depression.
P2860
Q24632671-B15B5FFC-196F-4530-9F08-610FCAB296F8Q24652416-4EAB2C59-2E94-4BB8-8E91-A64299AB771DQ28570985-F37A48AA-E8C1-40D2-8906-4D022AC32C60Q28577195-2A40EC39-A221-4497-A149-31750F5EFD64Q30466408-6B1A4B19-21AB-44B0-B74A-F005F4AF8847Q30482553-D31D30E1-F504-4F02-BEE7-1ECC980F4FD9Q33778781-722CBC96-0128-49E2-8578-9C038B0A0DE1Q33812736-37294A42-2364-456B-97C6-A2708C0A4E0DQ34180539-ECC47661-88EC-4563-8F81-B43B690FD213Q34897152-9C41454C-4B89-499C-930F-34208341A113Q35110498-BD0DECAC-4EB4-4A9B-BCF1-8AD9C593CF23Q35110517-90B36B03-2262-42E4-A6AB-E1BBFA1F072FQ36061656-5AE1A558-3BC4-49C6-9897-4C119A746A81Q36260312-08792FAB-A3DD-456E-9490-A075FF81EBFDQ36518248-3FD17CFB-7954-4F24-BB4D-938A9438776DQ36787458-EF513467-655D-42AE-9AE8-2F1F507830B2Q36789832-D710C2C9-DBBD-43AC-9E3C-9F2757A8EBD5Q37276146-23523738-BBC3-4E18-923C-B2B303F901ECQ37384128-307677BD-8E73-413B-B93A-DADA761B453CQ37640340-F61ACCCA-2E3E-46BC-806C-0F2967888D95Q37686124-C79D0B02-17EA-4CED-9FF1-D52ADC3E7162Q37861570-00F39AF6-5C9E-43AB-95C4-26CAA77458C5Q37883455-6E8FA84B-5AEB-4210-9120-5FAA8F7CAD7DQ37987472-D26EE20B-D87A-4BC6-8D7F-6CA73A03F5FEQ38011623-B560CAE9-3D04-423D-8191-04769189700AQ38025661-16A68F84-9B33-4750-9D89-CE516898AEBBQ38088346-3480B4A1-9418-499A-9EC3-2989C060C2E7Q38121110-29A8E966-6D6F-4BE7-9FE2-6F2F5032D1BFQ38136260-65421461-C7E8-4F9D-86A0-9AB16017E48CQ38681565-DC767EC2-A869-49A9-A856-AEB3A20DE53EQ38915577-05879E2D-4C36-49C1-8232-66D9BDE1D5E9Q39218587-2C742E9D-B218-4445-9D2A-9183E03627F0Q41436081-08A760BA-990A-4B00-95A5-700B75C763A3Q41829270-269AB9A9-D887-47DF-A8A0-567255F52FB4Q44743311-316F3349-82A9-451F-9AD7-F50D272249D0Q46200045-D671CB36-1A86-49CB-A47D-F59F2E228723Q47103471-F1B2EF2B-433B-4F2E-BDCB-A9003EC304E6Q47415985-A6D8AE20-C5DF-4ECC-9ACE-F07800AE31F2Q47676203-79E46629-4C85-4D1E-BC62-08CEE3FF7512Q47787596-435C53EA-BA75-48FF-8B32-9C5127CF7B3A
P2860
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
@en
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
@nl
type
label
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
@en
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
@nl
prefLabel
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
@en
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
@nl
P2093
P2860
P1433
P1476
Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
@en
P2093
Jaime L Bellamy
Paul L Durham
Roger K Cady
P2860
P356
10.1111/J.1526-4610.2006.00294.X
P577
2006-01-01T00:00:00Z